These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 28780376)

  • 1. Retinoic acid induction of CD1d expression primes chronic lymphocytic leukemia B cells for killing by CD8
    Ghnewa YG; O'Reilly VP; Vandenberghe E; Browne PV; McElligott AM; Doherty DG
    Clin Immunol; 2017 Oct; 183():91-98. PubMed ID: 28780376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoic acid regulates CD1d gene expression at the transcriptional level in human and rodent monocytic cells.
    Chen Q; Ross AC
    Exp Biol Med (Maywood); 2007 Apr; 232(4):488-94. PubMed ID: 17392484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes.
    Fais F; Morabito F; Stelitano C; Callea V; Zanardi S; Scudeletti M; Varese P; Ciccone E; Grossi CE
    Int J Cancer; 2004 Apr; 109(3):402-11. PubMed ID: 14961579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.
    Weinkove R; Brooks CR; Carter JM; Hermans IF; Ronchese F
    Haematologica; 2013 Mar; 98(3):376-84. PubMed ID: 23065503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells.
    Schneiders FL; Huijts CM; Mantici A; Menks MA; Scotet E; Veerhuis R; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2015 May; 158(1):92-9. PubMed ID: 25796193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d.
    Clark K; Yau J; Bloom A; Wang J; Venzon DJ; Suzuki M; Pasquet L; Compton BJ; Cardell SL; Porcelli SA; Painter GF; Zajonc DM; Berzofsky JA; Terabe M
    Front Immunol; 2019; 10():2355. PubMed ID: 31649670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amide analogues of CD1d agonists modulate iNKT-cell-mediated cytokine production.
    Wojno J; Jukes JP; Ghadbane H; Shepherd D; Besra GS; Cerundolo V; Cox LR
    ACS Chem Biol; 2012 May; 7(5):847-55. PubMed ID: 22324848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of alpha-galactosylceramide impairs the survival of dendritic cell subpopulations in vivo.
    Simkins HM; Hyde E; Farrand KJ; Ong ML; Degli-Esposti MA; Hermans IF; Ronchese F
    J Leukoc Biol; 2011 May; 89(5):753-62. PubMed ID: 21297009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness.
    Balreira A; Cavallari M; Sá Miranda MC; Arosa FA
    Immunobiology; 2010 Jun; 215(6):505-13. PubMed ID: 19651460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
    Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
    Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and functional activity of labeled CD1d glycolipid agonists.
    Jervis PJ; Polzella P; Wojno J; Jukes JP; Ghadbane H; Garcia Diaz YR; Besra GS; Cerundolo V; Cox LR
    Bioconjug Chem; 2013 Apr; 24(4):586-94. PubMed ID: 23458425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
    Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
    Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro.
    Zeng SG; Ghnewa YG; O'Reilly VP; Lyons VG; Atzberger A; Hogan AE; Exley MA; Doherty DG
    J Immunol; 2013 Aug; 191(4):1666-76. PubMed ID: 23851681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative modulation of invariant natural killer T cell responses to glycolipid antigens by p38 MAP kinase.
    Stuart JK; Bisch SP; Leon-Ponte M; Hayatsu J; Mazzuca DM; Maleki Vareki S; Haeryfar SM
    Int Immunopharmacol; 2010 Sep; 10(9):1068-76. PubMed ID: 20584631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GM2 ganglioside inhibits iNKT cell responses in a CD1d-dependent manner.
    Pereira CS; Ribeiro H; Pérez-Cabezas B; Cardoso MT; Alegrete N; Gaspar A; Leão-Teles E; Macedo MF
    Mol Genet Metab; 2018 Sep; 125(1-2):161-167. PubMed ID: 30030044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-glycosidic compounds can stimulate both human and mouse iNKT cells.
    Jukes JP; Gileadi U; Ghadbane H; Yu TF; Shepherd D; Cox LR; Besra GS; Cerundolo V
    Eur J Immunol; 2016 May; 46(5):1224-34. PubMed ID: 26873393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD1d-restricted antigen presentation by Vγ9Vδ2-T cells requires trogocytosis.
    Schneiders FL; Prodöhl J; Ruben JM; O'Toole T; Scheper RJ; Bonneville M; Scotet E; Verheul HM; de Gruijl TD; van der Vliet HJ
    Cancer Immunol Res; 2014 Aug; 2(8):732-40. PubMed ID: 24934445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.
    Guillaume J; Pauwels N; Aspeslagh S; Zajonc DM; Elewaut D; Van Calenbergh S
    Bioorg Med Chem; 2015 Jul; 23(13):3175-82. PubMed ID: 26003341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.